Quadrature Capital Ltd Has $5.14 Million Stock Position in Icon Plc $ICLR

Quadrature Capital Ltd cut its holdings in Icon Plc (NASDAQ:ICLR) by 18.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,333 shares of the medical research company’s stock after selling 7,834 shares during the period. Quadrature Capital Ltd’s holdings in Icon were worth $5,135,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Artisan Partners Limited Partnership increased its stake in Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after buying an additional 2,893,946 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Icon by 21.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock valued at $545,730,000 after acquiring an additional 650,379 shares in the last quarter. Equity Investment Corp acquired a new stake in shares of Icon in the second quarter valued at about $82,264,000. Cantillon Capital Management LLC bought a new stake in Icon during the second quarter worth about $67,663,000. Finally, First Pacific Advisors LP raised its holdings in Icon by 76.3% during the second quarter. First Pacific Advisors LP now owns 964,120 shares of the medical research company’s stock worth $140,231,000 after acquiring an additional 417,173 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Icon in a research note on Tuesday. Citigroup restated a “neutral” rating and set a $200.00 target price (down from $225.00) on shares of Icon in a report on Thursday, August 21st. TD Cowen dropped their price target on shares of Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research report on Friday, October 24th. Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, Leerink Partners set a $220.00 target price on shares of Icon in a report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $205.00.

Icon Price Performance

NASDAQ:ICLR opened at $183.82 on Friday. The company has a market cap of $14.84 billion, a P/E ratio of 24.87, a P/E/G ratio of 3.04 and a beta of 1.22. The firm’s fifty day moving average price is $174.60 and its two-hundred day moving average price is $162.68. Icon Plc has a one year low of $125.10 and a one year high of $228.29. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.